Page last updated: 2024-12-05

piperazine adipate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Piperazine adipate is a salt formed from the reaction of piperazine with adipic acid. It has been investigated for its potential therapeutic effects in various conditions, including epilepsy, Parkinson's disease, and cancer. Studies have shown that piperazine adipate can exhibit anticonvulsant activity and may possess neuroprotective properties. The compound's mechanism of action involves modulating neurotransmitter systems and influencing calcium channel activity. However, research on piperazine adipate is still ongoing, and further investigations are needed to fully understand its pharmacological properties and potential clinical applications.'

piperazine adipate : A piperazinium salt obtained by combining equimolar amounts of piperazine and adipic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8905
CHEMBL ID3276110
CHEBI ID133924
SCHEMBL ID1642955
MeSH IDM0047007

Synonyms (80)

Synonym
AKOS015839637
adipic acid; piperazine
piperazine, monoadipate
einecs 205-569-0
oxyzin (van)
hexanedioic acid, compound with piperazine (1:1)
vermicompren (tabl.)
ai3-20824
nsc 74383
oxyzin (tabl.)
142-88-1
vermilass
wln: t6n dntj & qv4vq
oxypaat
divermex
pipadox
nsc74383
adiprazine
arduvermin
nsc-74383
dietelmin
piperazine adipate
adiprazina
oxurasin
piperaskat
piperascat
nometan
helmirazin
vermicompren
camin ap (tn)
piperazine adipate (jp17/usp)
D02145
hexanedioic acid--piperazine (1/1)
CHEBI:133924
piperazinium adipate
piperazinium hexanedioate
piperazine-1,4-diium hexanedioate
hexanedioic acid - piperazine (1:1)
hexanedioic acid; piperazine
P0448
ec 205-569-0
piperazine adipate (1:1)
piperazine adipate [usp:jan]
unii-v7p5p122lb
v7p5p122lb ,
S4443
piperazine adipate [mart.]
piperazine, hexanedioate (1:1)
piperazine adipate [mi]
piperazine adipate [usp monograph]
piperazine adipate [usp-rs]
piperazine, adipate (1:1)
piperazine adipate [green book]
piperazini adipas [who-ip latin]
piperazine adipate [jan]
piperazine adipate [who-ip]
piperazine adipate [ep monograph]
piperazine adipate [who-dd]
CHEMBL3276110
SCHEMBL1642955
DTXSID2059724
CS-7763
W-109511
piperazine adipate, united states pharmacopeia (usp) reference standard
piperazine adipate, european pharmacopoeia (ep) reference standard
piperazine adipate; piperazine hexanedioate
HY-B2186
FT-0751551
142-88-1 (adipate)
mfcd00050650
hexanedioic acid;piperazine
vermicompren;adiprazine
BCP32242
E78817
Q27291639
piperazine hexanedioic acid
piperazine adipate 100 microg/ml in water
BS-42127
piperazinehexanedioicacid
EN300-82962

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" canis eggs shed into the environment, but that multiple dosing remains essential for this purpose."( Studies on the control of Toxocara canis in breeding kennels.
Dick, IG; Fisher, MA; Hutchinson, MJ; Jacobs, DE, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anthelminthic drugSubstance intended to kill parasitic worms (helminths).
antinematodal drugA substance used in the treatment or control of nematode infestations.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
piperazinium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1150404Anthelmintic activity against Syphacia obvelata infected in mouse assessed as reduction in worm burden at 300 mg/kg, po bid for 5 days1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Anthelmintic 1-cinnamamido-2,4-imidazolidinediones.
AID1150406Anthelmintic activity against Syphacia obvelata infected in mouse assessed as reduction in worm burden at 50 mg/kg, po bid for 5 days1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Anthelmintic 1-cinnamamido-2,4-imidazolidinediones.
AID1150405Anthelmintic activity against Syphacia obvelata infected in mouse assessed as reduction in worm burden at 100 mg/kg, po bid for 5 days1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Anthelmintic 1-cinnamamido-2,4-imidazolidinediones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (86.21)18.7374
1990's4 (13.79)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.59 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index42.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.56%)4.05%
Observational0 (0.00%)0.25%
Other37 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]